Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.60 |
| ▸ | EGFR | P00533 | 5/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.43 |
| ▸ | GAK | O14976 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14283168 | 0.87 | TRPV1 (0.47) | TRPV1EGFRBACE1BACE2KDR | |
| SCHEMBL5739486 | 0.80 | EGFR (0.63) | TRPV1EGFRCNR1GAKKDR | |
| SCHEMBL4975227 | 0.78 | TRPV1 (0.75) | TRPV1EGFREPHX2KDR | |
| SCHEMBL4973865 | 0.76 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL4682148 | 0.75 | BACE1 (0.46) | TRPV1EGFRBACE1EPHX2KDR | |
| SCHEMBL5740105 | 0.73 | EGFR (0.69) | TRPV1EGFRCNR1GAKEPHX2 | |
| SCHEMBL5741068 | 0.73 | BACE1 (0.43) | EGFRBACE1BACE2CTSD | |
| SCHEMBL20406640 | 0.72 | EGFR (0.49) | EGFREPHX2FLT3 | |
| SCHEMBL6033643 | 0.71 | TRPV1 (0.54) | TRPV1EGFREPHX2 | |
| SCHEMBL18013046 | 0.71 | EGFR (0.66) | TRPV1EGFRCNR1GAKEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1890223-A | Capsaicin receptor agonists | NEUROGEN CORP (US) | 2007-01-03 | — | — | CN | claimed |
| US-20060194805-A1 | Capsaicin receptor agonists | NEUROGEN CORPORATION (US) | 2006-08-31 | — | — | US | claimed |
| EP-1678149-A2 | 4-AMINO(AZA)QUINOLINE DERIVATIVES AS CAPSAICIN RECEPTOR AGONISTS | NEUROGEN CORPORATION (US) | 2006-07-12 | — | — | EP | claimed |
| WO-2005042498-A2 | 4-AMINO (AZA) QUINOLINE DERIVATIVES AS CAPSAICIN RECEPTOR AGONISTS | NEUROGEN CORPORATION (US) | 2005-05-12 | — | — | WO | claimed |
| US-20060194805-A1 | Capsaicin receptor agonists | NEUROGEN CORPORATION (US) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194805-A1 | Capsaicin receptor agonists | TRPV1, HCAR1, CNR1 | TRPV1 1/4885EGFR 3398/4885CNR1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.